Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.30 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.30 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22326695 | 0.83 | MAP4K4 (0.43) | MAP4K4RIPK1TNIK | |
| SCHEMBL64667 | 0.77 | MAP4K4 (0.44) | MAP4K4RIPK1TNIKENPP1ACVRL1 | |
| SCHEMBL20820178 | 0.76 | MAP4K4 (0.47) | MAP4K4RIPK1TNIKENPP1ACVRL1 | |
| SCHEMBL15740086 | 0.75 | MAP4K4 (0.46) | MAP4K4RIPK1TNIKACVRL1TNK2 | |
| SCHEMBL17238976 | 0.73 | MAP4K4 (0.44) | MAP4K4RIPK1TNIKEGFRKDR | |
| SCHEMBL13075167 | 0.73 | MAP4K4 (0.44) | MAP4K4RIPK1TNIK | |
| SCHEMBL57305 | 0.73 | MAP4K4 (0.44) | MAP4K4RIPK1TNIK | |
| SCHEMBL25714861 | 0.73 | MAP4K4 (0.44) | MAP4K4RIPK1TNIKACVRL1EGFR | |
| SCHEMBL21943279 | 0.73 | PI4KA (0.36) | MAP4K4CSNK2A2CSNK2A1PI4KAPI4K2B | |
| SCHEMBL19402915 | 0.73 | MAP4K4 (0.41) | MAP4K4RIPK1TNIKACVRL1TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20230322813-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023168254-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168194-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| WO-2020205867-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | MAP4K4 2827/4885RIPK1 920/4885TNIK 890/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | MAP4K4 3096/4885RIPK1 923/4885TNIK 947/4885 |
| US-10980825-B2 | Cyclic dinucleotide | STING1, CGAS, MAVS | MAP4K4 3096/4885RIPK1 923/4885TNIK 947/4885 |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | MAP4K4 3096/4885RIPK1 923/4885TNIK 947/4885 |
| US-20230322813-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | MAP4K4 4104/4885RIPK1 4055/4885TNIK 3778/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | MAP4K4 4104/4885RIPK1 4055/4885TNIK 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.